You need to be approved for last line treatment first before moving up the treatment ladder.
novartis have had to do another P3 trial psmafore to prove pluvicto is better than chemo. This is still pending if it is a success.
- Forums
- ASX - By Stock
- CU6
- Ann: First participant treated in the last dose escalation cohort
Ann: First participant treated in the last dose escalation cohort, page-13
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.09 |
Change
-0.210(4.88%) |
Mkt cap ! $1.272B |
Open | High | Low | Value | Volume |
$4.30 | $4.30 | $4.08 | $3.493M | 835.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 7459 | $4.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.12 | 9361 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 7459 | 4.090 |
1 | 2450 | 4.080 |
3 | 2089 | 4.070 |
1 | 10000 | 4.060 |
3 | 7617 | 4.050 |
Price($) | Vol. | No. |
---|---|---|
4.120 | 9361 | 1 |
4.160 | 10000 | 1 |
4.170 | 15000 | 1 |
4.190 | 600 | 1 |
4.240 | 1500 | 1 |
Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
$4.10 |
  |
Change
-0.210 ( 4.15 %) |
|||
Open | High | Low | Volume | ||
$4.17 | $4.29 | $4.08 | 50363 | ||
Last updated 15.59pm 21/05/2024 ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
AUQ
ALARA RESOURCES LIMITED
Stephen Gethin, Non-Executive Director & Chairman
Stephen Gethin
Non-Executive Director & Chairman
Previous Video
Next Video
SPONSORED BY The Market Online